RESUMEN
Tick-borne encephalitis (TBE) virus is the most prevalent tick-transmitted orthoflavivirus in Europe. Due to the nonspecific nature of its symptoms, TBE is primarily diagnosed by ELISA-based detection of specific antibodies in the patient serum. However, cross-reactivity between orthoflaviviruses complicates the diagnosis. Specificity issues may be mitigated by serum neutralization assays (SNT), although the handling of clinically relevant orthoflaviviruses requires biosafety level (BSL) 3 conditions and they have highly divergent viral kinetics and cell tropisms. In the present study, we established a reporter virus particle (RVP)-based SNT in which the infectivity is measured by luminescence and that can be performed under BSL-2 conditions. The RVP-based SNT for TBEV exhibited a highly significant correlation with the traditional virus-based SNT (R2 = 0.8637, p < 0.0001). The RVP-based assay demonstrated a sensitivity of 92.3% (95% CI: 79.7%-97.4%) and specificity of 100% (95% CI: 81.6%-100%). We also tested the cross-reactivity of serum samples in RVP-based assays against other orthoflaviviruses (yellow fever virus, dengue virus type 2, Zika virus, West Nile virus and Japanese encephalitis virus). Interestingly, all serum samples which had tested TBEV-positive by ELISA but negative by RVP-based SNT were reactive for antibodies against other orthoflaviviruses. Thus, the RVP-based seroneutralization assay provides an added value in clinical diagnostics as well as in epidemiological studies.
Asunto(s)
Anticuerpos Antivirales , Reacciones Cruzadas , Virus de la Encefalitis Transmitidos por Garrapatas , Encefalitis Transmitida por Garrapatas , Ensayo de Inmunoadsorción Enzimática , Pruebas de Neutralización , Sensibilidad y Especificidad , Virus de la Encefalitis Transmitidos por Garrapatas/inmunología , Humanos , Anticuerpos Antivirales/sangre , Pruebas de Neutralización/métodos , Encefalitis Transmitida por Garrapatas/diagnóstico , Encefalitis Transmitida por Garrapatas/virología , Ensayo de Inmunoadsorción Enzimática/métodos , Virión/inmunología , Anticuerpos Neutralizantes/sangre , Anticuerpos Neutralizantes/inmunología , AnimalesRESUMEN
Introduction: Lyme disease (LD) affects â¼476,000 people each year in the United States. Symptoms are variable and include rash and flu-like symptoms. Reasons for the wide variation in disease outcomes are unknown. Powassan virus (POWV) is a tick-borne flavivirus that causes disease ranging from asymptomatic infection to encephalitis, neurologic damage, and death. POWV and LD geographic case distributions overlap, with Ixodes species ticks as the common vectors. Clinical ramifications of coinfection or sequential infection are unknown. Objectives: This study's primary objective was to determine the prevalence of POWV-reactive antibodies in sera samples collected from previously studied cohorts of individuals with self-reported LD history residing in the Northeastern United States. As a secondary objective, we studied clinical differences between people with self-reported LD history and low versus high POWV antibody levels. Methods: We used an enzyme-linked immunosorbent assay (ELISA) to quantify IgG directed at the POWV envelope (E) protein domain III in 538 samples from individuals with self-reported LD history and 16 community controls. The samples were also tested with an ELISA assay to quantify IgG directed at the POWV NS1 protein. Results: The percentage of individuals with LD history and possible evidence of POWV exposure varied depending on the assay utilized. We found no significant difference in clinical symptoms between those with low or high POWV IgG levels in the in-house assay. Congruence of the EDIII and NS1 assays was low with only 12% of those positive in the in-house EDIII ELISA testing positive in the POWV NS1 ELISA. Conclusions: The results highlight the difficulty in flavivirus diagnostic testing, particularly in the retrospective detection of flavivirus exposure. The findings suggest that a prospective study with symptomatic patients using approved clinical testing is necessary to address the incidence and clinical implications of LD and POWV co-infection or sequential infection.
Asunto(s)
Virus de la Encefalitis Transmitidos por Garrapatas , Encefalitis Transmitida por Garrapatas , Ixodes , Enfermedad de Lyme , Animales , Humanos , Estados Unidos/epidemiología , Prevalencia , Estudios Retrospectivos , Estudios Prospectivos , Encefalitis Transmitida por Garrapatas/veterinaria , Enfermedad de Lyme/epidemiología , Enfermedad de Lyme/veterinaria , New England/epidemiología , Anticuerpos Antivirales , Inmunoglobulina GRESUMEN
Flaviviruses such as dengue virus (DENV), Zika virus (ZIKV), and yellow fever virus (YFV) are spread by mosquitoes and cause human disease and mortality in tropical areas. In contrast, Powassan virus (POWV), which causes severe neurologic illness, is a flavivirus transmitted by ticks in temperate regions of the Northern hemisphere. We find serologic neutralizing activity against POWV in individuals living in Mexico and Brazil. Monoclonal antibodies P002 and P003, which were derived from a resident of Mexico (where POWV is not reported), neutralize POWV lineage I by recognizing an epitope on the virus envelope domain III (EDIII) that is shared with a broad range of tick- and mosquito-borne flaviviruses. Our findings raise the possibility that POWV, or a flavivirus closely related to it, infects humans in the tropics.
Asunto(s)
Anticuerpos Neutralizantes , Humanos , Brasil , Anticuerpos Neutralizantes/inmunología , México , Anticuerpos Antivirales/inmunología , Animales , Virus de la Encefalitis Transmitidos por Garrapatas/inmunología , Flavivirus/inmunología , Epítopos/inmunología , Anticuerpos Monoclonales/inmunología , Garrapatas/virología , Garrapatas/inmunología , Femenino , MasculinoRESUMEN
A vacina viva atenuada do vírus da febre amarela (YFV) pode, em casos raros, causar doença com risco de vida, geralmente em pacientes sem história prévia de doença viral grave. A deficiência completa de IFNAR1 autossômica recessiva (AR) foi relatada em um paciente de 12 anos de idade. Aqui, nós estudamos sete outros pacientes previamente saudáveis ââcom idades entre 13 e 80 anos com doença inexplicável associada à vacina YFV com risco de vida. Um paciente de 13 anos tinha deficiência completa de IFNAR2 de AR. Três outros pacientes vacinados com idades de 47, 57 e 64 anos apresentaram altos títulos de auto-Abs circulantes contra pelo menos 14 dos 17 IFNs do tipo I individuais. Esses anticorpos foram recentemente demonstrados como subjacentes a pelo menos 10% dos casos de pneumonia COVID-19 com risco de vida. Os auto-Abs foram neutralizantes in vitro, bloqueando o efeito protetor do IFN-α2 contra cepas vacinais de YFV. A deficiência de AR IFNAR1 ou IFNAR2 e auto-Abs neutralizantes contra IFNs do tipo I foram responsáveis ââpor mais da metade dos casos de doença associada à vacina YFV com risco de vida estudados aqui. Indivíduos previamente saudáveis ââpodem ser testados para ambas as predisposições antes da vacinação anti-YFV.